1. The Court made favorable observations about the Biowatch principle on costs in constitutional litigation, noting that it applies where the litigation is not frivolous, vexatious, or instituted without probable cause. The Court noted that Mr Jeewan's litigation, while unsuccessful, was not improper or without merit given the guidance in Chirwa that employees should first pursue LRA mechanisms. 2. The Court commented that Transnet's late abandonment of the jurisdiction and res judicata issues, rather than formally abandoning those aspects of the judgment earlier, caused unnecessary inconvenience to Mr Jeewan in having to prepare arguments on those issues. This conduct influenced the Court's decision on costs. 3. The Court noted that while the Prescription Act does limit rights guaranteed by section 34 of the Constitution, this does not automatically require re-interpretation in every case - the specific circumstances and nature of the claim must be considered. 4. The Court observed that when a claimant states that a claim arises from infringement of common law rights to enforce a contract, "then that is the claim, as a fact, and the court must deal with it accordingly" - the court must take the claim as pleaded even if it might be a bad claim. 5. The Court noted the important social policy behind prescription periods as articulated in Road Accident Fund v Mdeyide: the need for certainty and stability in legal affairs, maintaining quality of adjudication, and respecting the rule of law by deciding disputes based on the best available evidence while memories are fresh and evidence is available.